Patents by Inventor Nicolas E.S. Guisot

Nicolas E.S. Guisot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of Rho-associated protein kinase
    Patent number: 11878020
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE
    Publication number: 20230021916
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Application
    Filed: August 26, 2022
    Publication date: January 26, 2023
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E.S. Guisot
  • Modulators of Rho-associated protein kinase
    Patent number: 11497751
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 15, 2022
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • Modulators of Rho-associated Protein Kinase
    Publication number: 20210038606
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E.S. Guisot
  • Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
    Patent number: 9975897
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 22, 2018
    Assignee: Loxo Oncology, Inc.
    Inventors: Mathew Calder, Nicolas E. S. Guisot
  • Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase
    Publication number: 20170129897
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 11, 2017
    Inventors: Mathew Calder, Nicolas E.S. Guisot